Microprobe, Inc.

Oridigm Corporation

Genetic Systems Corporation

Mediquest Therapeutics, Inc.

Dennis E Schwartz

Roy H Kanemoto

Nicolaas M Vermeulen

Christine L O'Day

Susan M Watanabe

Kim Dix

Allan Sachs Hoffman

Nicolaas M J Vermeulen

John H Priest

Robert C Nowinski

Nicolaas M Vermuelen

Elaine K Thomas

Trevor H Adams

A new paradigm of disease centers around the metabolic pathways of S-adenosyl-L-methionine (SAM), the intermediates of these pathways and other metabolic pathways influenced by the SAM pathways. Methods are provided to analyze and modulate SAM pathways associated with a disease or condition. Such methods permit identification and utilization of diagnostic and therapeutic protocols and agents for such disease states and conditions.

S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy

S-adenosyl methionine regulation of metabolic pathways and its use in

Disclosed are novel methods, combinations of agents and kits for use in killing, or inhibiting the growth of, microorganisms. Enhanced antimicrobial action is provided by using a methylation inhibitor, as exemplified by using an agent that inhibits methylation or maturation of bacterial RNA in combination with, e.g., a macrolide lincosamide streptogramin B (MLS) antibiotic. The methods and compositions described may be employed to reduce the resistance of susceptible microorganisms to antimicrobial agents and thus to treat animals or patients with infections.

Combinations and methods for reducing antimicrobial resistance

This invention relates to compositions of oligonucleotide probes for use in the detection of bacteria associated with medical disorders of the human mouth, wherein said probes consist essentially of a segment of nucleic acid capable of selectively hybridizing under hybridizing conditions, to the 16S or 23S ribosomal RNA [rRNA] of said bacteria. Methods for detection, as well as diagnostic kits for the assay of these bacterium, are also disclosed.

Oligonucleotide probes for detection of periodontal pathogens

This invention provides for a method of quantifying bacteria using a bacterial specific nucleic acid probe which is complementary to a unique and highly conserved region of the 16S ribosomal RNA (rRNA) of bacteria. This probe permits the rapid detection of 16S rRNA in a sample and by comparison with known standards, one can estimate the total bacterial count in the sample. The method is accurate and reproducible and conducted at temperatures of between about 120.degree. to about 40.degree. C.

Quantification of bacteria using a nucleic acid hybridization assay

Oligonucleotide probes for the detection of periodontal pathogens

This invention relates to methods for using volume exclusion agents to enhance in situ hybridization rates between short oligonucleotide probes and their target polynucleotides where the cells containing the target polynucleotides are adhered onto a glass substrate. In one aspect, the invention specifically relates to the use of volume exclusion agents to facilitate assay and diagnostic procedures for the detection of a virus, such as human papillomavirus (HPV). In addition, diagnostic kits embracing the above methods are described herein.

Use of volume exclusion agents for the enhancement of in situ

Methods and compounds are disclosed for determining the presence, amount of, or association between substances of interest in samples suspected of containing same. The methods are based on the polymerization-induced separation of specifically-bound, reporter-labeled recognition reactants from free, reporter-labeled recognition reactants. The methods described are applicable to any substance for which suitable recognition reactants exist or can be made and are not limited by considerations such as chemical composition or molecular size.

Polymerization-induced separation assay using recognition pairs

Growing community of inventors

Redmond, WA, United States of America

Dennis E Schwartz